Literature DB >> 15538968

Following a TRAIL: update on a ligand and its five receptors.

Fiona C Kimberley1, Gavin R Screaton.   

Abstract

Identification of tumour necrosis factor apoptosis inducing ligand (TRAIL), a TNF family ligand, sparked a torrent of research, following an initial observation that it could kill tumour cells, but spare normal cells. Almost a decade after its discovery, and with five known receptors, the true physiological role of TRAIL is still debated and its anti-tumorigenic properties limited by potential toxicity. This review takes a comprehensive look at the story of this enigmatic ligand, addressing its remaining potential as a therapeutic and providing an overview of the TRAIL receptors themselves.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538968     DOI: 10.1038/sj.cr.7290236

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  56 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  Following the TRAIL from hepatitis C virus and alcohol to fatty liver.

Authors:  S C Afford; D H Adams
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

3.  Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.

Authors:  Rachel M Locklin; Ermanno Federici; Belen Espina; Philippa A Hulley; R Graham G Russell; Claire M Edwards
Journal:  Mol Cancer Ther       Date:  2007-12-07       Impact factor: 6.261

4.  Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Authors:  Rentian Feng; Qin Tong; Zhaojun Xie; Haizi Cheng; Lirong Wang; Suzanne Lentzsch; G David Roodman; Xiang-Qun Xie
Journal:  Mol Carcinog       Date:  2015-01-16       Impact factor: 4.784

5.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

6.  Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity.

Authors:  Harmeet Malhi; Fernando J Barreyro; Hajime Isomoto; Steven F Bronk; Gregory J Gores
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

Review 7.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 8.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

9.  Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.

Authors:  Xiaozhen Zhang; Astrid C Frank; Christine M Gille; Marybeth Daucher; Juraj Kabat; Steven Becker; Richard A Lempicki; Karoll J Cortez; Michael A Polis; G Mani Subramanian; Shyam Kottilil
Journal:  Hepatol Res       Date:  2009-09-25       Impact factor: 4.288

10.  Expression of the TRAIL receptors in blood mononuclear cells in leukemia.

Authors:  Ugur Deligezer; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.